Study design and patients
ELN
CHRONIC MYELOID LEUKEMIA
ASCEMBL is an ongoing, phase 3, global, multi‐center, open‐label, randomized, active‐controlled study (Figure ASCEMBL study design. CML‐CP, chronic myeloid leukemia in chronic phase; FPFV, First patient first visit; MCyR, major cytogenetic response; TKI, tyrosine kinase inhibitors. Key exclusion criteria were the presence of T315I or V299L mutations (i.e., known bosutinib‐resistant Patients who failed bosutinib based on efficacy (based on 2013 ELN guidelines) could switch to asciminib within 96 weeks after the last patient completed the randomized study treatment (protocol amendment; December 14, 2018). Bosutinib patients were not allowed to switch to asciminib if they discontinued bosutinib due to intolerance or for any reasons other than lack of efficacy. Data collected for patients receiving asciminib after switching from bosutinib are not included in the present analysis.